Percutaneous mitral valve interventions: overview of new approaches.

The percutaneous management of valvular heart disease has recently been receiving a great deal of interest as an area of great potential. Innovative technologies are now being developed to treat mitral regurgitation. Although there are established surgical techniques for treating organic mitral regurgitation, the surgical management of functional mitral regurgitation remains controversial, and such patients have a poor prognosis. Therefore, a percutaneous treatment for functional mitral regurgitation holds great clinical potential. Having a nonsurgical approach available may be attractive to patients with organic mitral valve regurgitation as well. Several approaches and devices have been designed to treat specifically functional mitral regurgitation, and some of these have been applied to humans in early-stage evaluations. The MitraClip device (Abbott Laboratories, Abbott Park, IL) has been used to treat both functional and degenerative mitral valve regurgitation and has been compared to surgery in the EVEREST II (Endovascular Valve Edge-to-Edge Repair Study II) randomized trial. Although the field of percutaneous management of mitral regurgitation is at an early stage, it has been demonstrated that percutaneous approaches can reduce mitral regurgitation, suggesting there is a great deal of potential for clinical benefit to patients with mitral regurgitation.